BioCryst Pharmaceuticals, Inc.
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-44.9% vs price
Base Case (Median)
20.8% vs price
Bull Case (75th pct.)
115.8% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $6.87 | -29.1% | High (40%) |
| EV/EBITDA | $16.56 | 70.8% | Medium (20%) |
| EV/FCF | $34.03 | 250.8% | Medium (20%) |
| Earnings Power Value | $0.74 | -92.3% | Medium (50%) |
Based on 4 out of 8 methods, BCRX appears fairly valued at the current price of $9.70. The base case fair value of $11.72 implies 20.8% upside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.